Biologic Therapy in HIV: To Screen or Not to Screen

Biologic therapy has revolutionized the management of chronic inflammatory diseases, including inflammatory bowel disease (IBD). Before the initiation of therapy, it is critical to rule out prior infection of chronic hepatitis B virus (HBV) and tuberculosis (TB). However, screening for human immunod...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Willam, Vavilin, Ilan, Malhotra, Nidhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312554/
https://www.ncbi.nlm.nih.gov/pubmed/34336440
http://dx.doi.org/10.7759/cureus.15941
_version_ 1783729168340484096
author Davis, Willam
Vavilin, Ilan
Malhotra, Nidhi
author_facet Davis, Willam
Vavilin, Ilan
Malhotra, Nidhi
author_sort Davis, Willam
collection PubMed
description Biologic therapy has revolutionized the management of chronic inflammatory diseases, including inflammatory bowel disease (IBD). Before the initiation of therapy, it is critical to rule out prior infection of chronic hepatitis B virus (HBV) and tuberculosis (TB). However, screening for human immunodeficiency virus (HIV) is not as routinely completed. We present a case of a 56-year-old male on ustekinumab for the management of Crohn’s disease, found to have undiagnosed human immunodeficiency virus (HIV) with progression to acquired immunodeficiency syndrome (AIDS). 
format Online
Article
Text
id pubmed-8312554
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-83125542021-07-29 Biologic Therapy in HIV: To Screen or Not to Screen Davis, Willam Vavilin, Ilan Malhotra, Nidhi Cureus Gastroenterology Biologic therapy has revolutionized the management of chronic inflammatory diseases, including inflammatory bowel disease (IBD). Before the initiation of therapy, it is critical to rule out prior infection of chronic hepatitis B virus (HBV) and tuberculosis (TB). However, screening for human immunodeficiency virus (HIV) is not as routinely completed. We present a case of a 56-year-old male on ustekinumab for the management of Crohn’s disease, found to have undiagnosed human immunodeficiency virus (HIV) with progression to acquired immunodeficiency syndrome (AIDS).  Cureus 2021-06-26 /pmc/articles/PMC8312554/ /pubmed/34336440 http://dx.doi.org/10.7759/cureus.15941 Text en Copyright © 2021, Davis et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Gastroenterology
Davis, Willam
Vavilin, Ilan
Malhotra, Nidhi
Biologic Therapy in HIV: To Screen or Not to Screen
title Biologic Therapy in HIV: To Screen or Not to Screen
title_full Biologic Therapy in HIV: To Screen or Not to Screen
title_fullStr Biologic Therapy in HIV: To Screen or Not to Screen
title_full_unstemmed Biologic Therapy in HIV: To Screen or Not to Screen
title_short Biologic Therapy in HIV: To Screen or Not to Screen
title_sort biologic therapy in hiv: to screen or not to screen
topic Gastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312554/
https://www.ncbi.nlm.nih.gov/pubmed/34336440
http://dx.doi.org/10.7759/cureus.15941
work_keys_str_mv AT daviswillam biologictherapyinhivtoscreenornottoscreen
AT vavilinilan biologictherapyinhivtoscreenornottoscreen
AT malhotranidhi biologictherapyinhivtoscreenornottoscreen

Ejemplares similares